Who are Vascace's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Renormax, Aceon, Lotensin, Accupril, Monopril, Altace.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cilazapril.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vascace — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vascace (CILAZAPRIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cilazapril. Area: Cardiovascular.

phase 2 cilazapril Angiotensin-converting enzyme Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Vascace (CILAZAPRIL). Cilazapril blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vascace TARGET	CILAZAPRIL		phase 2	cilazapril	Angiotensin-converting enzyme
Renormax	SPIRAPRIL HYDROCHLORIDE		marketed	spirapril	Angiotensin-converting enzyme	1994-01-01
Aceon	PERINDOPRIL ARGININE	Symplmed Pharms Llc	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1993-01-01
Lotensin	BENAZEPRIL	Validus Pharms	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Accupril	QUINAPRIL	Pfizer	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Monopril	FOSINOPRIL		marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Altace	RAMIPRIL	King Pfizer	marketed	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-10-05 — Aceon · 7846961 · US
2039-08-16 — Altace · 12343338 · Formulation · US

Sponsor landscape (cilazapril class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vascace — Competitive Intelligence Brief. https://druglandscape.com/ci/cilazapril. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing